Validation, Publication, and Maintenance of real-world data sources and studies in the HMA-EMA RWD Catalogues

The purpose of this SOP is to describe the steps and procedures concerning the validation, publication, and maintenance of data sources and studies within the HMA-EMA Catalogues of real-world data (RWD) sources and studies. The principles and activities described will apply specifically to EMA staff responsible for the validation of the Catalogues’ content. The same principles will apply to the Catalogues’ users when submitting entries.

Acces this publication
European Medicines Agency (EMA)

Year of publication

2025

ISBN

SOP/TDA/3543; EMA/467789/2024

Source

European Medicines Agency (EMA)

Author

European Medicines Agency (EMA)

You might also be interested in

ERDERA 2026 Open Session

From individual cases to new treatment pathways: ERDERA Open Session focuses on ultra-rare diseases

ERDERA marked the close of its second year with an Open Session on ultra-rare diseases, bringing together European, regulatory and scientific perspectives on how innovation can reach patients.
Training online

Information Webinar – ERDERA Joint Transnational Call 2027

December 14 @ 3:00 pm - 4:00 pm
This information webinar on the 2027 Joint Transnational Call for Proposals is scheduled for 14 December 2026.
Cover of the 16-country rare disease policy assessment, October 2026.

Reckoning With the Rare Disease Landscape. A 16 Country Policy Landscape Assessment across the Life Course.

The assessment compares diagnosis, treatment access and national governance across 16 countries, examining gaps in rare disease support throughout the life course.
erdera policy brief data OCT2026

ERDERA Policy Brief: Making all data count for rare disease research and health outcomes – from policy recommendations to implementation

Making all data count for rare disease research and health outcomes – from policy recommendations to implementation

ERDERA Search